Recursion, Mila partner on tech-enabled drug discovery

By The Science Advisory Board staff writers

June 23, 2021 -- Digital biology company Recursion signed a multiyear deal with artificial intelligence (AI) research institute Mila to develop technology-enabled drug discovery.

Recursion leverages machine learning to unravel complex patterns of biology within biological datasets of more than 8 PB.

Under the deal, Recursion will open office space within Mila and build a team to improve its machine-learning capabilities. Mila's AI technology and experts will help Recursion improve the lives of patients while industrializing drug discovery.

Financial details of the collaboration were not disclosed.

ImmunoPrecise, Mila partner on antibody therapeutics
ImmunoPrecise Antibodies and artificial intelligence research institute Mila have formed a partnership to collaborate on research and talent development...
Recursion acquires Vium for drug discovery
Recursion has acquired Vium to advance its technologies and grow its drug discovery pipeline of over 30 programs.
Recursion launches dataset for COVID-19 drug discovery
Digital biology company Recursion has released an open-source RxRx19 dataset, the first human cellular morphological dataset of SARS-CoV-2, it said.

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter